180928 banner 1920x560 2

LUPUS ACADEMY ON-DEMAND

Matricule-se já Grátis
0764 card on%20demand 28 09
18 vídeos

Descrição do curso

Acesse aqui o conteúdo gravado durante o XXXV Congresso Brasileiro de Reumatologia 2018

Categoria: REUMATOLOGIA


Informações gerais

Conteúdo
  • LUPUS ACADEMY ON-DEMAND
O que você vai aprender

    PHENOTYPING AND PATHOGENIC MECHANISMS IN LUPUS | MODERATORS: BEVRA HAHN (USA)
  • Which lupus is it? Phenotyping lupus in 2018 | Murray Urowitz (Canada)
  • Understanding pathogenic B-cell functions in SLE: Where we are with new therapeutic targets? | Thomas Dorner (Germany)
  • CLASSIFICATION CRITERIA FOR LUPUS | MODERATORS: BEVRA HAHN (USA) & MURRAY UROWITZ (CANADA)
  • Evolution of SLE classification criteria | Ian Bruce (UK)
  • WHAT’S NEW IN LUPUS NEPHRITIS | MODERATORS: RICH FURIE (USA) & BEVRA HAHN (USA)
  • Classification of lupus nephritis: What’s new? | Brad Rovin (USA)
  • Emerging therapies for lupus nephritis | Liz Lightstone (UK)
  • Lupus nephritis: Dialysis and transplant | Evandro Klumb (Brazil)
  • TREAT-TO-TARGET: CLINICAL AND PATIENT OUTCOMES | MODERATORS: DAVID ISENBERG (UK)
  • Current treatment targets in lupus | Rich Furie (USA)
  • Remission and low disease activity as treatment targets in lupus | Ronald van Vollenhoven (Netherlands)
    • Ronald van Vollenhoven (Netherlands)

      Vídeo
  • Quality of life as a treatment target in lupus | Matthias Schneider (Germany)
  • MANAGEMENT OF LUPUS | MODERATORS: ELOISA BONFA (BRAZIL) & RICARD CERVERA (SPAIN)
  • Biomarkers to predict flares | Judith James (USA)
  • Preventing damage (atherosclerosis, bone disease, infection and malignancy) | David Isenberg (UK)
  • CURBSIDE CONSULTS | MODERATOR: THOMAS DORNER (GERMANY)
  • The experts tackle three short challenging cases | David Isenberg (UK) Zahir Amoura (France) Munther Khamashta (UK/UAE) Bevra Hahn (USA)
    • David Isenberg (UK) Zahir Amoura (France) Munther Khamashta (UK/UAE) Bevra Hahn (USA)

      Vídeo
  • CNS DISEASE | MODERATORS: BERNARDO PONS-ESTEL (ARGENTINA) & ANDREA DORIA (ITALY)
  • Clinical phenotypes and the management of neuropsychiatric lupus | Bevra Hahn (USA)
  • Update on imaging in neuropsychiatric lupus | Simone Appenzeller (Brazil)
  • SIMPÓSIO SATÉLITE GSK – O BELIMUMABE NA MUDANÇA DE PROGNÓSTICO DOS PACIENTES COM LÚPUS ERITEMATOSO SISTÊMICO
  • Evaluation Of Use of Belimumab in Clinical Practice Settings: 18 Months Results in Argentina | Mercedes Argentina García
  • Application of belimumab to Practice: Who is the ideal patient? | Richard Furie
  • Belimumab in 2018: Long-term Safety and Reduced Organ Damage Progression | Roger A. Levy
  • Discussão